New quadruple immunotherapy attack on childhood cancer
NCT ID NCT05754684
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests a combination of four immune-based treatments for children whose neuroblastoma has returned or not responded to standard care. The therapy includes natural killer cells from a relative, two antibodies (dinutuximab beta and naxitamab), immune-boosting cytokines, and a drug called spironolactone. The goal is to see if this powerful mix can shrink tumors and improve survival in 29 young patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Natural killer cells, dinutuximab beta, interleukin-2, GM-CSF, spironolactone, and naxitamab
What this could lead to
If it works, this could offer a new treatment option for children with hard-to-treat neuroblastoma that has come back or not responded to standard therapy.
What could go wrong
This is a small, early-phase trial with only 29 participants, so results may not apply broadly. The combination of multiple immune therapies may cause significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA RECURRENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hong Kong Children's Hospital
RECRUITINGHong Kong, Hong Kong
Contact Phone: •••-•••-•••• Email: •••••@•••••